Psyence Biomedical Ltd.
PBM
$2.70
-$0.04-1.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 101.98% | 17.62% | -1,018.12% | -1,221.42% | -1,480.05% |
| Total Depreciation and Amortization | 2,000.00% | 3,000.00% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -108.84% | -18.28% | 103,504.63% | 51,570.47% | 35,277.08% |
| Change in Net Operating Assets | 67.08% | -547.77% | -169.75% | -174.51% | -179.29% |
| Cash from Operations | -26.78% | -18.46% | -9.15% | -37.07% | -81.95% |
| Capital Expenditure | -68.97% | -279.31% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -179.31% | -389.66% | -- | -- | -- |
| Total Debt Issued | -60.00% | 17.73% | 289.51% | 639.16% | -- |
| Total Debt Repaid | -- | 0.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 171.63% | -106.26% | -104.61% | -100.00% |
| Cash from Financing | 289.46% | 148.79% | 39.39% | 57.83% | 108.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 998.84% | 3,283.16% | 240.66% | 934.71% | -21.61% |